Bristol Private Equity Club
VC Fund
Bristol, United States
Bristol Private Equity Club is an investment firm that invests in its members with businesses in the schemes SEIS and EIS venture capital.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 32%
Last updated:
For AI agents: llms.txt
Industries Bristol Private Equity Club invests in
Stages Bristol Private Equity Club invests in
Countries Bristol Private Equity Club invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $566k–$5.5M
- Pre-Seed
- $377k–$2M
Investment Focus
Industry
- Health Care 3 (10%)
- Biotechnology 3 (10%)
- SaaS 2 (6%)
- Sensor 2 (6%)
- Chemical 2 (6%)
Stage
- Seed 12 (39%)
- Pre-Seed 5 (16%)
- Funding Round 4 (13%)
- Venture - Series Unknown 2 (6%)
- Grant 1 (3%)
Country
- United Kingdom 19 (61%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mark Mason
Founder Member
|
Founder Member | Total investments: 0 | Find email | |
|
Steve Vangasse
Member
|
Member | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Ceryx Medical is developing bioelectronics based on unique, patent protected, chip technology which is able to mimic nerve centres within the body called Central Pattern Generators (CPGs).These CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate and even walking.It is hoped thatCeryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury. | $6.8M / Venture - Series Unknown / Jun 11, 2025 | |
|
|
Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. They show how their proprietary modification of smallinterfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. | $2.3M / Jul 17, 2024 | |
|
|
Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $5.5M / Seed / May 30, 2024 | |
|
|
Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $5.5M / Seed / May 30, 2024 | |
|
|
Anaphite is a manufacturer of electrodes by replacing energy-intensive wet processes with scalable, low-carbon dry-coating technology. | $1.1M / Seed / Mar 13, 2024 | |
|
|
Delta g is a gravity sensing hardware and technology development company that has developed a cutting-edge underground imaging system that leverages quantum technology. It is a spinout from the University of Birmingham. | $2M / Pre-Seed / Jul 05, 2023 | |
|
|
Albotherm offers a smart transitioning coating technology that regulates the temperature of surfaces and structures without the need for energy input. When temperatures rise above a determined trigger temperature, our technology reversibly transitions from clear to white, reflecting away unwanted light to prevent overheating. | $2M / Seed / Jun 07, 2023 | |
|
|
spacebands creates software and wearable technology that aims to make workplaces safer. | $903.3K / Seed / Feb 17, 2023 | |
|
|
Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $3.7M / Seed / Feb 01, 2023 | |
|
|
Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $3.7M / Seed / Feb 01, 2023 | |
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bristol Private Equity Club invest in?
Bristol Private Equity Club invests primarily in Health Care, Biotechnology and SaaS startups, most often at Seed and Pre-Seed stage. Most of the 31 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bristol Private Equity Club's check size?
Bristol Private Equity Club typically joins rounds of $566k–$5.5M at Seed and $377k–$2M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bristol Private Equity Club participates in.
How do I contact Bristol Private Equity Club?
Public channels for Bristol Private Equity Club include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bristol Private Equity Club?
The team at Bristol Private Equity Club includes Mark Mason (Founder Member) and Steve Vangasse (Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!